KEY FINDINGS The global kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.52% during the forecast period, 2019-2028. The factors propelling the growth of the market are estimated to be the rising usage of minimally invasive processes, increasing research & development expenditure, and the growing prevalence of kidney cancer cases.
MARKET INSIGHTS There is an increasing prevalence of cancer, along with the rising adoption of early diagnosis.Some estimations suggest that there will be a 22% increase in kidney cases across the globe in 2020.
It is necessary to diagnose and treat kidney cancer at the earliest, since it is associated with several comorbidities. Recent advancements like the liquid biopsy technique are projected to result in healthy demand for kidney cancer diagnosis. There is an emphasis on using minimally-invasive techniques in surgical procedures.There has been an increase in the use of the minimally-invasive catheter-based endovascular procedure to regulate hypertension.
This has resulted in the growing adoption of kidney cancer treatment devices.These devices reduce cardiometabolic risks.
They also aid in minimizing hospital stay, since the procedure and the necessary processes do not take more than six hours.This restricts direct and indirect hospitalization costs.
Thus, rising minimally-invasive processes drive market growth. However, the high costs associated with the treatment and diagnosis, are projected to restrain the market growth.
REGIONAL INSIGHTS The analysis of the geographical division of the global kidney cancer therapeutics and diagnostics market includes the assessment of Asia Pacific, Europe, North America, and the rest of the world.North America dominated the global market in 2019.
The well-developed healthcare infrastructure and the presence of major companies are influencing the market growth prospects of the region.
COMPETITIVE INSIGHTS As per estimations, there will be intense competition between the well-established cancer therapeutics manufacturers. Some of the established players in the market include Bayer AG, Amgen Inc, Abbott Laboratories, Becton, Dickinson and Company (BD), etc.
Our report offerings include: • Explore key findings of the overall market • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions • Market Segmentation cater to a thorough assessment of key segments with their market estimations • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Companies mentioned 1. ABBOTT LABORATORIES 2. AMGEN INC 3. BAYER AG 4. BECTON, DICKINSON AND COMPANY (BD) 5. BRISTOL-MYERS SQUIBB COMPANY 6. EXELIXIS 7. F. HOFFMANN-LA ROCHE 8. MERCK & CO INC 9. MERCK KGAA 10. NOVARTIS INTERNATIONAL AG 11. NXSTAGE MEDICAL INC 12. PFIZER INC 13. SEATTLE GENETIC
Our reports have been used by over 10K customers, including:
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
Resorcinol Market report 2020 presents a strategic analysis of the global Resorcinol market over the forecast period from 2020 to 2026. The report presents a unique perspective on the future landscape of how COVID-19 transformed Resorcinol growth prospects. The overall economic recovery will be the main indicator of the Resorcinol market recovery...
Uveitis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2020, provides an overview of the Uveitis (Ophthalmology) pipeline landscape. Uveitis is swelling and irritation of the uvea, the middle layer of the eye....
Cholecystitis Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Cholecystitis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cholecystitis Clinical trials scenario.This report provides top line data relating to the clinical trials on Cholecystitis. Report...
200 pages •
By The Business Research Company
• Sep 2020
Major players in the anti-hypertensive drugs market are Merck & Co. Inc., Astra Zeneca Plc, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd. and Pfizer, Inc. The global anti-hypertensive drugs market is expected to decline from $26.1 billion in 2019 to $23.5 billion in 2020 at a compound annual growth rate (CAGR) of -9.7%. The...
Critical Care Therapeutics Market Research Report by Drug Class (Albumin, Antithrombin Concentrates, Factor XIII Concentrates, Fibrinogen Concentrates, and Prothrombin Complex Concentrates), by Application (Acute Coronary Syndrome, Atrial Fibrillation, Coronary Angioplasty, Deep Vein Thrombosis, and Hemodialysis) - Global Forecast...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.